Purple Biotech Q2 2026: $6.1M Cash Runway Through Mid-2027, IM1240 Advances Toward Clinic
PPBT sits 22% above its 52-week low of $1.16 on light trading volume (0.1× avg).
Summary
Purple Biotech's Q2 2026 results show a non-cash profit driven by warrant revaluation, with $6.1M in cash funding operations through mid-2027. The company is advancing IM1240 toward the clinic in 2027 but needs additional capital, while navigating a CEO transition.
Key Events · Earnings and Guidance · PPBT
-
Q2 2026 Net Profit Driven by Non-Cash Warrant Gain
Net income of $0.4M vs. a $1.1M loss in Q2 2025, entirely due to a $1.7M non-cash gain from warrant revaluation. Adjusted net loss was $1.2M, flat year-over-year.
-
Cash Runway Through Mid-2027
Cash and equivalents of $6.1M as of June 30, 2026, expected to fund operations through mid-2027 based on current plans. The company is pursuing strategic collaborations and financing alternatives to support the IM1240 Phase 1 trial.
-
IM1240 Preclinical Data Presented at EACR 2026
New data showed an 8-fold longer half-life and 16-fold greater systemic exposure vs. non-capped variant, with minimal cytokine release. Patient-derived tumor data demonstrated activity in PD-1-resistant and other hard-to-treat cancers.
-
IM1240 Clinical Entry Targeted for 2027
The lead CAPTN-3 candidate is advancing toward a first-in-human study in 2027, with a non-GLP toxicology study in non-human primates supporting the planned IND/CTA filing.
Analysis · PPBT · Life Sciences
Purple Biotech reported a net profit of $0.4M for Q2 2026, entirely due to a $1.7M non-cash gain from warrant revaluation — not operational improvement. The adjusted net loss was $1.2M, flat year-over-year. Cash of $6.1M provides runway through mid-2027, but the company is actively seeking a strategic collaboration or financing to fund the planned Phase 1 trial for lead candidate IM1240. New preclinical data presented at EACR 2026 further validates IM1240's differentiated safety and anti-tumor profile, supporting a 2027 clinical entry. The company also raised $2.3M through its ATM program in H1 2026, diluting existing shareholders. The recent CEO transition to a part-time role adds leadership uncertainty as the company approaches a critical financing milestone.
At the time of this filing, PPBT was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $1.16 to $24.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.